Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Export

@article{citeulike:4096688, abstract = {The impact of irbesartan treatment on biomarkers of low-grade inflammation, endothelial dysfunction, growth factors, and advanced glycation end products (AGEs) during the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study was evaluated. IRMA 2 was a 2-year multicenter, randomized, double-blind trial in patients comparing irbesartan (150 or 300 mg once daily) versus placebo. The primary end point was onset of overt nephropathy. A subgroup (n = 269, 68\%) was analyzed for biomarkers at baseline and after 1 and 2 years. High-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, fibrinogen, adhesion molecules, transforming growth factor-beta, and AGE peptides were assessed. Irbesartan treatment yielded significant changes in hs-CRP (based on generalized estimating equation regression coefficient) with a 5.4\% decrease per year versus a 10\% increase per year in the placebo group (P < 0.001). Fibrinogen decreased 0.059 g/l per year from baseline versus placebo's 0.059 g/l increase per year (P = 0.027). IL-6 showed a 1.8\% increase per year compared with placebo's 6.5\% increase per year (P = 0.005). Changes in IL-6 were associated with changes in albumin excretion (P = 0.04). There was no treatment effect on the other biomarkers. Irbesartan (300 mg once daily) reduces low-grade inflammation in this high-risk population, and this may reduce the risk of micro- and macrovascular disease.}, author = {Persson, F. and Rossing, P. and Hovind, P. and Stehouwer, C. D. and Schalkwijk, C. and Tarnow, L. and Parving, H. H.}, citeulike-article-id = {4096688}, citeulike-linkout-0 = {http://dx.doi.org/10.2337/db06-0827}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/17130503}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=17130503}, doi = {10.2337/db06-0827}, issn = {0012-1797}, journal = {Diabetes}, keywords = {arb, dn, rct, uae}, month = {December}, number = {12}, pages = {3550--3555}, posted-at = {2009-02-25 07:08:36}, priority = {2}, title = {Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.}, url = {http://dx.doi.org/10.2337/db06-0827}, volume = {55}, year = {2006} }

TY - JOUR ID - citeulike:4096688 L3 - citeulike-article-id:4096688 N2 - The impact of irbesartan treatment on biomarkers of low-grade inflammation, endothelial dysfunction, growth factors, and advanced glycation end products (AGEs) during the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study was evaluated. IRMA 2 was a 2-year multicenter, randomized, double-blind trial in patients comparing irbesartan (150 or 300 mg once daily) versus placebo. The primary end point was onset of overt nephropathy. A subgroup (n = 269, 68%) was analyzed for biomarkers at baseline and after 1 and 2 years. High-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, fibrinogen, adhesion molecules, transforming growth factor-beta, and AGE peptides were assessed. Irbesartan treatment yielded significant changes in hs-CRP (based on generalized estimating equation regression coefficient) with a 5.4% decrease per year versus a 10% increase per year in the placebo group (P < 0.001). Fibrinogen decreased 0.059 g/l per year from baseline versus placebo's 0.059 g/l increase per year (P = 0.027). IL-6 showed a 1.8% increase per year compared with placebo's 6.5% increase per year (P = 0.005). Changes in IL-6 were associated with changes in albumin excretion (P = 0.04). There was no treatment effect on the other biomarkers. Irbesartan (300 mg once daily) reduces low-grade inflammation in this high-risk population, and this may reduce the risk of micro- and macrovascular disease. IS - 12 JF - Diabetes SN - 0012-1797 EP - 3555 TI - Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. VL - 55 SP - 3550 KW - arb KW - dn KW - rct KW - uae AU - Persson, F AU - Rossing, P AU - Hovind, P AU - Stehouwer, CD AU - Schalkwijk, C AU - Tarnow, L AU - Parving, HH PY - 2006/12// UR - http://dx.doi.org/10.2337/db06-0827 ER -